A novel mutation panel for predicting etoposide resistance in small-cell lung cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Haddadin S, Perry MC. History of small-cell lung cancer. Clin Lung Cancer. 2011;12(2):87–93. doi:10.1016/j.cllc.2011.03.00221550554
   PubMed Web of Science ®Google Scholar
• Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc. 2008;83:355–367. doi:10.4065/83.3.35518316005
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975–2014, National Cancer Institute. Bethesda, MD, based on November 2016 SEER data submission, posted to the SEER website, April 28, 2017. Available from: https://seer.cancer.gov/csr/1975_2014/. Accessed April 28, 2017.
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19. doi:10.1007/978-3-319-24223-1_126667336
   PubMed Web of Science ®Google Scholar
• Conen K, Hagmann R, Hess V, et al. Incidence and predictors of Bone metastases (BM) and Skeletal-related events (SREs) in Small cell lung cancer (SCLC): a Swiss patient cohort. J Cancer. 2016;7:2110–2116. doi:10.7150/jca.1621127877227
   PubMed Web of Science ®Google Scholar
• Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593–a phase III trial of the eastern cooperative oncology group. J Clin Oncol. 2001;19:2114–2122. doi:10.1200/JCO.2001.19.8.211411304763
   PubMed Web of Science ®Google Scholar
• Jett JR, Schild SE, Kesler KA, et al. Treatment of small-cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(5Suppl):e400S–e419S. doi:10.1378/chest.12-236323649448
   PubMed Web of Science ®Google Scholar
• SEER cancer statistics review. 1975–2009. Available from: https://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER website, April 30, 2012. Accessed April 30, 2012.
   Google Scholar
• Stinchcombe TE, Gore EM. Limited-stage small-cell lung cancer: current chemoradiotherapy treatment paradigms. Oncologist. 2010;15:187–195. doi:10.1634/theoncologist.2009-029820145192
   PubMed Web of Science ®Google Scholar
• Morabito A, Carillio G, Daniele G, et al. Treatment of small-cell lung cancer. Crit Rev Oncol Hematol. 2014;9:257–270. doi:10.1016/j.critrevonc.2014.03.003
   Web of Science ®Google Scholar
• Früh M, De Ruysscher D, Popat S, et al. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi99–vi105. doi:10.1093/annonc/mdt17823813929
   PubMed Web of Science ®Google Scholar
• Ogino H, Hanibuchi M, Kakiuchi S, et al. Analysis of the prognostic factors of extensive disease small-cell lung cancer patients intokushima university hospital. J Med Invest. 2016;63:286–293.27644574
   PubMedGoogle Scholar
• Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85–91. doi:10.1056/NEJMoa00303411784874
   PubMed Web of Science ®Google Scholar
• Hermes A, Bergman B, Bremnes R, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol. 2008;26:4261–4267. doi:10.1200/JCO.2007.15.754518779613
   PubMed Web of Science ®Google Scholar
• Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage. J Clin Oncol. 2006;24:2038–2043. doi:10.1200/JCO.2005.04.859516648503
   PubMed Web of Science ®Google Scholar
• Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27:2530–2535. doi:10.1200/JCO.2008.20.106119349543
   PubMed Web of Science ®Google Scholar
• Schmittel A, Sebastian M, Fischer von Weikersthal L, et al. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin. Ann Oncol. 2011;22:1798–1804. doi:10.1093/annonc/mdq65221266516
   PubMed Web of Science ®Google Scholar
• Zatloukal P, Cardenal F, Szczesna A, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol. 2010;21(9):1810–1816. doi:10.1093/annonc/mdq03620231298
   PubMed Web of Science ®Google Scholar
• Kim DW, Kim HG, Kim JH, et al. Randomized phase III trial of irinotecan plus cisplatin versus etoposide plus cisplatin in chemotherapy-naïve Korean patients with extensive-disease small-cell lung cancer. Cancer Res Treat. 2019;51:119–127. doi:10.4143/crt.2018.01929529858
   PubMed Web of Science ®Google Scholar
• Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30:1692–1698. doi:10.1200/JCO.2011.40.490522473169
   PubMed Web of Science ®Google Scholar
• Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol. 1999;17:1794–1801. doi:10.1200/JCO.1999.17.6.179410561217
   PubMed Web of Science ®Google Scholar
• Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;63(11–12):1727–1733.526911
   PubMedGoogle Scholar
• van Meerbeeck JP, Fennell DA, de Ruysscher DK. Small-cell lung cancer. Lancet. 2011;378(9804):1741–1755. doi:10.1016/S0140-6736(11)60984-721565397
   PubMed Web of Science ®Google Scholar
• Dingemans AM, Witlox MA, Stallaert RA, et al. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small-cell lung cancer. Clin Cancer Res. 1999;5:2048–2058.10473085
   PubMed Web of Science ®Google Scholar
• Viktorsson K, De Petris L, Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun. 2005;331:868–880. doi:10.1016/j.bbrc.2005.03.19215865943
   PubMed Web of Science ®Google Scholar
• Yang W, Soares J, Greninger P, et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955–61. doi:10.1093/nar/gks111123180760
   PubMed Web of Science ®Google Scholar
• Bonanno L, Favaretto A, Rugge M, et al. Role of genotyping in non-small-cell lung cancer treatment: current status. Drugs. 2011;71:2231–2246. doi:10.2165/11597700-000000000-0000022085382
   PubMed Web of Science ®Google Scholar
• Chiu HW, Chang JS, Lin HY, et al. FBXL7 upregulation predicts a poor prognosis and associates with a possible mechanism for paclitaxel resistance in ovarian cancer. J Clin Med. 2018;7(10):330. doi:10.3390/jcm7100330
   PubMed Web of Science ®Google Scholar
• Chiu HW, Lin HY, Tseng IJ, et al. OTUD7B upregulation predicts a poor response to paclitaxel in patients with triple-negative breast cancer. Oncotarget. 2017;9:553–565. doi:10.18632/oncotarget.2307429416635
   PubMedGoogle Scholar
• Mayakonda A, Lin DC, Assenov Y, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–1756. doi:10.1101/gr.239244.11830341162
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. doi:10.1093/nar/gkv00725605792
   PubMed Web of Science ®Google Scholar
• George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small-cell lung cancer. Nature. 2015;524(7563):47–53. doi:10.1038/nature1466426168399
   PubMed Web of Science ®Google Scholar
• Liu SQ, Yu JP, Yu HG, et al. Activation of Akt and ERK signalling pathways induced by etoposide confer chemoresistance in gastric cancer cells. Dig Liver Dis. 2006;38:310–318. doi:10.1016/j.dld.2006.01.01216527552
   PubMedGoogle Scholar
• Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003;421(6922):499–506. doi:10.1038/nature0136812556884
   PubMed Web of Science ®Google Scholar
• Lans H, Marteijn JA, Vermeulen W. ATP-dependent chromatin remodeling in the DNA-damage response. Epigenetics Chromatin. 2012;5:4. doi:10.1186/1756-8935-5-422289628
   PubMed Web of Science ®Google Scholar
• Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314.13298683
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ, Lum JJ, Hatzivassiliou G, et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11–20. doi:10.1016/j.cmet.2007.10.00218177721
   PubMed Web of Science ®Google Scholar
• Majewski N, Nogueira V, Bhaskar P, et al. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell. 2004;16:819–830. doi:10.1016/j.molcel.2004.11.01415574336
   PubMed Web of Science ®Google Scholar
• Buzzai M, Bauer DE, Jones RG, et al. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene. 2005;24:4165–4173. doi:10.1038/sj.onc.120862215806154
   PubMed Web of Science ®Google Scholar
• Xu N, Lao Y, Zhang Y, et al. Akt: a double-edged sword in cell proliferation and genome stability. J Oncol. 2012;2012:951724. doi:10.1155/2012/95172422481935
   PubMedGoogle Scholar
• Makinoshima H, Takita M, Saruwatari K, et al. Signaling through the Phosphatidylinositol 3-kinase (PI3K)/Mammalian target of Rapamycin(mTOR) axis is responsible for aerobic glycolysis mediated by glucose transporter in Epidermal growth factor receptor(EGFR) -mutated lung adenocarcinoma. J Biol Chem. 2015;290:17495–17504. doi:10.1074/jbc.M115.66049826023239
   PubMed Web of Science ®Google Scholar
• Grilley-Olson JE, Keedy VL, Sandler A, et al. A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small-cell lung cancer. Oncologist. 2015;20:105–106. doi:10.1634/theoncologist.2014-032725616430
   PubMed Web of Science ®Google Scholar
• Spigel DR, Greco FA, Rubin MS, et al. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer. Lung Cancer. 2012;77:359–364. doi:10.1016/j.lungcan.2012.03.00922560921
   PubMed Web of Science ®Google Scholar